A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis